Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-19T20:04:53.168Z Has data issue: false hasContentIssue false
  • English
  • Français

Calcium channel antagonists – pharmacological differences and their clinical relevance to elderly patients

Published online by Cambridge University Press:  17 November 2008

Stephen Dalton  and
Hilary Wynne
Stephen Dalton
Affiliation:
University of Newcastle upon Tyne, Newcastle upon Tyne, UK
Hilary Wynne*
Affiliation:
University of Newcastle upon Tyne, Newcastle upon Tyne, UK
*
Ward 15 Office, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Clinical geriatrics
Information
Reviews in Clinical Gerontology , Volume 6 , Issue 1 , February 1996 , pp. 57 - 62
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Catterall, WA. Structure and function of voltage sensitive ion channels. Science 1988; 242: 50–61.Google Scholar
2Rampe, D, Su, CM, Yousif, F, Triggle, DJ. Calcium channel antagonists: pharmacological considerations. Br J Clin Pharmacol 1985; 20: 2475–545.CrossRefGoogle ScholarPubMed
3Katz, AM, Hager, WD, Messineo, FC, Pappano, AJ. Cellular actions and pharmacology of the calcium channel blocking drugs. Am J Med 1984; 77 (2B) 2–10.Google Scholar
4Gould, BA, Hornung, RS, Mann, S et al. Slow channel inhibitors verapamil and nifedipine in the management of hypertension. J Cardiovasc Pharmacol 1982; 4: S369–73.Google Scholar
5Kurnik, PB, Tifennbrunn, AJ, Ludbrook, PA. The dependence of the cardiac effects of nifedipine on the responses of the peripheral vascular system. Circulation 1984; 69: 963–72.CrossRefGoogle ScholarPubMed
6Robertson, DRC, Walker, DC, Renwick, AG, George, CF. Age-related changes in the pharamcokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297–305.CrossRefGoogle Scholar
7Takenaka, T, Asano, M, Shiono, K, Shibaski, M, Inagaki, O. Cardiovascular pharmacology of nicardipine in animals. Br J Clin Pharmacol 1985; 20: 7S–22S.CrossRefGoogle ScholarPubMed
8Welzel, D, Burger, KJ, Weidinger, G. Calcium antagonists as first line antihypertensive agents: a placebocontrolled comparative trial of isradipine and nifedipine. J Cardiovasc Pharmacol 1990; 15 (suppl 1): S70–74.Google Scholar
9Rofman, BA. Long-term evaluation of amlodipine versus hydroclorothiazide in patients with essential hypertension. J Cardiovasc Pharmacol 1988; 12 (suppl 7): S98–102.Google Scholar
10 Nimodipine for delayed cerebral ischaemia after subarachnoid haemorrhage. Drug Ther Bull 1992; 21: 81–82.CrossRefGoogle Scholar
11Woelfel, A, Foster, JR, McAllister, RG et al. Efficacy of verapamil in exercise induced ventricular tachycardia. Am J Cardiol 1985; 56: 292–97.Google Scholar
12Schwartz, JB. Aging alters verapamil elimination and dynamics: single dose-steady state responses. J Pharmacol Exp Ther 1990; 255: 364–73.Google Scholar
13Schwartz, JB, Capili, H, Daugherty, J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55: 509–17.CrossRefGoogle ScholarPubMed
14Chaffman, M, Brogden, RN. Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29: 387–454.CrossRefGoogle ScholarPubMed
15Kelly, JG, O'Malley, K. Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokinet 1992; 22: 416–33.CrossRefGoogle ScholarPubMed
16Schwartz, JB, Capili, H, Wainer, IW. Verapamil stereoisomers during racemic verapamil administration. Effects of aging and comparisons of administration to individual stereoisomers. Clin Pharmacol Ther 1994; 56: 368–76.CrossRefGoogle ScholarPubMed
17Wynne, H, Cope, L, Mutch, E, Rawlins, MD, Woodhouse, KW, James, OFW. The effect of age upon liver size and liver blood flow in man. Hepatology 1989; 9: 297–301.Google Scholar
18Roberts, SJ, Bateman, DN. The use of nitrates, calcium channel blockers and ACE inhibitors in primary care in the Northern Region: a pharmaco-epidemiological study. Br J Clin Pharmacol 1994; 38: 489–97.CrossRefGoogle Scholar
19Medical Research Council Working Party. MRC trial of hypertension in elderly adults: principal results. BMJ 1992; 304: 405–12.Google Scholar
20SHEP Cooperative Research Group. Prevention of stroke in antihypertensive drug treatment in older patients with isolated systolic hypertension. JAMA 1991; 265: 3255–84.Google Scholar
21Dahlof, B, Lindholm, LH, Hanson, L, Sherson, B, Ekbom, T, Webster, PO. Mortality and morbidity in the Swedish trial of old patients with hypertension (STOP-hypertension). Lancet 1991; 338: 1281–85.CrossRefGoogle ScholarPubMed
22Buhler, FR, Boli, P, Erne, P et al. Position of calcium antagonists in antihypertensive therapy. J Cardiovasc Pharmacol 1985; 7: 21–27.CrossRefGoogle ScholarPubMed
23Vestal, RE, Wood, AJJ, Shand, DG. Reduced beta-adrenoreceptor sensitivity in the elderly. Clin Pharmacol Ther 1979; 26: 181–86.Google Scholar
24Chalmers, JP, Smith, SA, Wing, LMH. Hypertension in the elderly, the role of calcium antagonists. J Cardiovasc Pharmacol 1988; 12 (suppl 8): S147–55.CrossRefGoogle ScholarPubMed
25Forette, F, Bellet, M, Henry, JF et al. Effect of nicardipine in elderly hypertensive patients. Br J Clin Pharmacol 1985; 20: 125–95.CrossRefGoogle ScholarPubMed
26Findlay, IN, MacLeod, K, Gillen, G et al. Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function. Br Heart J 1987; 57: 336–43.CrossRefGoogle Scholar
27Findlay, IN, MacLeod, K, Gillen, G et al. A double blind placebo controlled comparison of verapamil, atenolol and their combination in patients with chronic stable angina pectoris. Br Heart J 1986; 55: 240–45.Google Scholar
28Watson, SD, Harris, F. Diltiazem, nifedipine and verapamil: their effects in patients with stable angina. Am J Cardiol 1990; 66: 779–85.Google Scholar
29Akhras, F, Jackson, G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991; 228: 1036–39.CrossRefGoogle Scholar
30Nolan, L, O'Malley, K. Prescribing for the elderly: Part 1. Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–49.CrossRefGoogle Scholar
31Williams, BO, Caird, FI, Lennox, IM. Haemodynamic response to postural stress in the elderly with and without postural hypotension. Age Ageing 1985; 14: 193–201.Google Scholar
32Pringle, SD, McEwan, CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. BMJ 1987; 294: 155–56.Google Scholar
33Staffurth, JS, Emery, P. Adverse interaction between nifedipine and beta blockade [Letter]. BMJ 1981 282: 225.Google Scholar
34Le Jeunne, C, Hugues, FC, Munera, Y, Ozanne, H. Dizziness in the elderly and calcium channel blockers. Biomed Pharmacother 1991; 45: 3–6.CrossRefGoogle Scholar
35Ramoska, EA, Spiller, HA, Myers, A. Calcium channel blocker toxicity. Ann Emerg Med 1990; 19: 649–53.Google Scholar
36Sever, P, Beevers, G, Bulpitt, C et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983–98.CrossRefGoogle ScholarPubMed